Abstracts tagged "remission and treatment"

Abstract Number: 2632 • 2019 ACR/ARP Annual Meeting
Changing Trends in the Management of ANCA-associated Vasculitis at an Academic Medical Center
Sana Afroz¹ and Najia Shakoor ², ¹RUMC, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: For years, cyclophosphamide (CYC) has been the primary treatment for severe anca-associated vasculitides (AAV) and has significantly improved disease related mortality. In addition, maintenance…
Abstract Number: 1559 • 2017 ACR/ARHP Annual Meeting
Residual Disease Activity in Psoriatic Arthritis Triggers Treatment Adjustment in Only a Quarter of Patients in Daily Clinical Practice
Leonieke van Mens¹, Sadaf Atiqi², Inka Fluri², Marleen van de Sande³, Arno van Kuijk⁴ and Dominique Baeten¹, ¹AMC, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ³Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Reade, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: With expanding therapeutic possibilities for the treatment of psoriatic arthritis (PsA) it will be increasingly important to determine residual disease and define when to…
Abstract Number: 2280 • 2017 ACR/ARHP Annual Meeting
Effectiveness of Switching to Adalimumab As the Second- and Third-Line Biological Drug in Patients with Juvenile Idiopathic Arthritis
Ekaterina Alexeeva¹, Tatiana Dvoryakovskaya², Victor Gladkikh^3,4, Andrei Moskalev^4,5, Rina Denisova¹, Ksenia Isaeva¹, Olga Lomakina¹, Margarita Soloshenko¹ and Anna Karaseva¹, ¹Reumatology department, Federal State Autonomous Institution"National Scientific and Practical Center of Children's Health"Of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, ²Pediatrics, The Federal State Autonomous Educational Institution of Higher Education The First Moscow State Medical University named after I.M. Sechenov Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation, ³Department of Biostatistics, EOL Labs ltd, Novosibirsk, Rwanda, ⁴Laboratory of Computational Physics, Institute of Computational Mathematics and Mathematical Geophysics SB RAS, Novosibirsk, Russian Federation, ⁵Department of Biostatistics, EOL Labs ltd, Novosibirsk, Russian Federation
Background/Purpose: The range of biological drugs currently used in JIA therapy includes not only anti-TNF but also other varieties. However, despite the high effectiveness and…
Abstract Number: 2289 • 2017 ACR/ARHP Annual Meeting
Individualized Prediction of Early Remission on Medication in Juvenile Idiopathic Arthritis
Jaime Guzman¹, Andrew Henrey², Thomas Loughin², Kiem Oen³, Natalie J. Shiff⁴, Roberta Berard⁵, Roman Jurencak⁶, Adam Huber⁷, Kerstin Gerhold⁸, Susanne Benseler⁹, Ciarán M. Duffy¹⁰ and Lori Tucker¹, ¹BC Children's Hospital, Vancouver, BC, Canada, ²Statistics and Actuarial Science, Simon Fraser University, Burnaby, BC, Canada, ³Department of Pediatrics and Child Health University of Manitoba, Winnipeg, MB, Canada, ⁴University of Florida, Gainesville, FL, ⁵Pediatrics, Children's Hospital, London Health Sciences Centre, London, ON, Canada, ⁶University of Ottawa, Ottawa, ON, Canada, ⁷IWK Health Centre, Halifax, NS, Canada, ⁸Pediatrics, University of Manitoba, Winnipeg, MB, Canada, ⁹Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ¹⁰Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada
Background/Purpose: The Research in Arthritis in Canadian Children emphasizing Outcomes cohort (ReACCh-Out) showed a 45% chance of attaining inactive disease within a year of…
Abstract Number: 956 • 2016 ACR/ARHP Annual Meeting
The Effect of Treatment Adjustments Aimed at DAS Remission on Physical Functioning in Undifferentiated and Rheumatoid Arthritis Patients in Low Disease Activity
SA Bergstra¹, OM Olivas Vergara¹, G Akdemir¹, GM Steup-Beekman², HK Ronday³, JB Harbers⁴, RBM Landewé^5,6 and CF Allaart¹, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²Department of Rheumatology, Bronovo Hospital, The Hague, Netherlands, The Hague, Netherlands, ³Department of Rheumatology, HAGA hospital, The Hague, Netherlands, The Hague, Netherlands, ⁴Department of Rheumatology, Franciscus Hospital, Roosendaal, Netherlands, Roosendaal, Netherlands, ⁵Amsterdam Medical Center, Amsterdam, Netherlands, ⁶Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands
Background/Purpose: Should we aim at remission if patients are in low disease activity (LDA)? We assessed if rheumatoid or undifferentiated arthritis (RA, UA) patients who…
Abstract Number: 1050 • 2016 ACR/ARHP Annual Meeting
Defining Low Disease Activity in Systemic Lupus Erythematosus
Ari Polachek¹, Dafna D Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Remission is a desirable but not a common enough outcome in systemic lupus erythematosus (SLE) and therefore additional measures are needed to evaluate new…
Abstract Number: 1694 • 2016 ACR/ARHP Annual Meeting
Does Treat to Target or Achieving Remission Improve Radiographic Outcome in Psa?
Laura C. Coates^1,2, Elizabeth M.A. Hensor^1,3, Paul Emery⁴, Philip G. Conaghan¹ and Philip S. Helliwell⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: The Tight Control of PsA (TICOPA) study was the first to address treat to target in PsA using the minimal disease activity (MDA)…
Abstract Number: 3209 • 2016 ACR/ARHP Annual Meeting
Clinical and Radiological Outcomes of 5 Years Remission Steered Treatment in Early Rheumatoid and Undifferentiated Arthritis Patients
Gülsah Akdemir¹, L. Heimans², R.J. Goekoop³, Maikel van Oosterhout⁴, J.B. Harbers⁵, C. Bijkerk⁶, G.M. Steup-Beekman⁷, L.R. Lard⁸, P.B.J. de Sonnaville⁹, B.A.M. Grillet¹⁰, TWJ Huizinga¹¹ and Cornelia F. Allaart², ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Haga Hospital, The Hague, Netherlands, ⁴Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁵Department of Rheumatology, Franciscus Hospital, Roosendaal, Netherlands, ⁶Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁷Rheumatology, Bronovo Hospital, The Hague, Netherlands, ⁸Rheumatology, MCH Antoniushove Hospital, Leidschendam, Netherlands, ⁹Rheumatology, ADRZ, Goes, Netherlands, ¹⁰Rheumatology, Zorgsaam, Terneuzen, Netherlands, ¹¹Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: To assess clinical and radiological outcomes of induction therapy followed by 5 years disease activity score (DAS)-remission steered treatment in early arthritis patients. Methods:…
Abstract Number: 568 • 2015 ACR/ARHP Annual Meeting
Superiority of Initial Combination- over Step up Therapy in Treatment to the Target of Remission in Daily Clinical Practice in Early Rheumatoid Arthritis Patients: Results from the DREAM Registry
Laura M.M. Steunebrink¹, G.A. Versteeg¹, Harald E. Vonkeman², Peter M. ten Klooster³, Ina H. Kuper¹, Arie E. van der Bijl⁴, Piet L.C.M. van Riel⁵ and Mart A.F.J. van de Laar¹, ¹Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ²Ariensplein 1, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ³Pcgr, University of Twente, Enschede, Netherlands, ⁴Isala Klinieken, Zwolle, Netherlands, ⁵Rheumatology, Bernhoven, Uden, Netherlands
Background/Purpose: Treat-to-target (T2T) of remission strategies has been widely accepted as the standard of care for patients with Rheumatoid Arthritis (RA). In early RA, implementation…
Abstract Number: 1662 • 2015 ACR/ARHP Annual Meeting
Treat to Target of Remission Is Effective but Not All Patients Are Always in Remission
Laura M.M. Steunebrink¹, Peter M. ten Klooster², Harald E. Vonkeman³, G.A. Versteeg¹, Arie E. van der Bijl⁴ and Mart A.F.J. van de Laar¹, ¹Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ²Psychology, Health & Technology, University of Twente, Enschede, Netherlands, ³Ariensplein 1, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ⁴Isala Klinieken, Zwolle, Netherlands
Background/Purpose: Presently the goals of rheumatoid arthritis (RA) therapy are to control symptoms, to prevent joint damage and disability. Attaining long-term clinical remission or at…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].